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Cutaneous melanoma (CM) is the leading cause of skin cancer 
mortality worldwide despite constituting only 4% of skin cancers. [1] 
The incidence of and mortality from invasive melanoma has risen 
steadily for at least the past two decades in most developed countries.[2]
Acral melanoma (AM) is a rare distinct variant of CM that arises 
from the palms, soles and nail apparatus. AMs account for only 1 - 
7% of all CMs diagnosed, and although the incidence of AM is the 
same for all racial and ethnic groups, it represents a disproportionate 
percentage of melanomas diagnosed in black, Hispanic and Asian 
individuals.[3-5]
The term AM includes all histopathological subtypes of melanoma 
that occur at acral sites, including acral lentiginous melanoma (ALM), 
which comprises up to 80% of all AMs.[4,6] First described by Reed in 
1976, ALM occurs preferentially at acral sites (i.e. palms, soles and 
nail apparatus) and demonstrates a radial lentiginous growth phase. [7] 
Recent studies suggest that ALMs have unique patterns of genetic 
mutations compared with other forms of CM.[8]
Soudry et al.[9] studied the clinicopathological features of AM in 45 
patients and found no difference between the ALM and non-ALM 
groups with reference to tumour characteristics, lymph node status 
and survival.[9] AM, regardless of histological subtype, is generally 
associated with a poorer prognosis than CM at other sites.[6,9,10] In 
a large population-based study of ALM in the USA, 5- and 10-year 
melanoma-specific survival rates were 80.3% and 67.5%, respectively, 
with significantly lower rates in individuals with darker skin types. [3] 
Prognostic data from the African continent are scarce, but 5-year 
survival rates as low as 26% for plantar melanomas in the black 
population have been reported.[11] Studies from Asia and Mexico 
also showed significantly lower survival rates in Hispanic and Asian 
populations.[1,12,13]
The poor prognosis associated with AM is generally attributed to 
late diagnosis and relatively higher Breslow thickness, but also to an 
intrinsic biological aggressiveness.[10]
Current knowledge on AM originates mainly from population-
based studies from North America, Europe and Asia,[1,12-16] with few 
data from the developing world.[4] Studies from Africa on this topic 
are limited and dated.[11,17,18] Hudson and Krige[17] investigated plantar 
CM in patients in Cape Town, South Africa (SA), between 1972 and 
1985 and reported that plantar CM accounted for 73% of all CMs in 
black African patients. In 71% of these cases ALM was identified as 
the histological subtype. A more recent report by York et al.[19] on 
primary cutaneous malignancies in the Northern Cape Province of 
SA showed that ALM was the subtype most commonly observed in 
all CMs diagnosed.
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Background. Acral melanoma (AM) is a rare subtype of cutaneous melanoma (CM) that disproportionately affects skin of colour and 
carries a poorer prognosis than other melanoma subtypes. The poor prognosis is attributed to late diagnosis and subsequent relatively high 
Breslow thickness, but also to an intrinsic biological aggressiveness. Scientific data on AM from the developing world are limited and a need 
exists to characterise the disease further in the South African (SA) population.
Objectives. To describe the clinical and pathological features of AM in an SA population.
Methodology. A retrospective chart review characterised the demographics, clinical features and histological data of 66 patients diagnosed 
with AM between January 2010 and June 2016 at Tygerberg Academic Hospital, Cape Town, SA.
Results. Sixty-six patients with AM were identified from 335 patients diagnosed with CM during the set time frame. The mean age (standard 
deviation (SD)) was 61.5 (12.5) years. Forty-two (63.6%) of the patients were female (male/female ratio 1:1.75). The majority of patients 
diagnosed with AM were black (48.5%), and the proportion of AM in black patients with CM was 80.0%. Fifty-six AMs (84.8%) were located 
on the foot and 10 (15.2%) on the hand. The median duration of the lesion before diagnosis was 10 months (range 2 - 84) and the mean (SD) 
tumour size was 3.8 (2.2) cm at diagnosis. The mean Breslow thickness of all AMs at diagnosis was 5.2 mm (median 4.2  mm, range 0 - 22). 
Stage of disease was known in 41 patients, 23 (56.1%) of whom had at least stage III disease at diagnosis. Mean Breslow thickness for foot 
and hand melanomas was 4.9 mm (range 0 - 22) and 6.9 mm (range 0 - 13.3), respectively (p=0.2552). The mean Breslow thickness in the 
black population was 6.3 mm compared with 4.2 mm and 4.3 mm, respectively, in the white and coloured populations (p=0.178). Patients 
from outside the Western Cape Province (WC) presented with a mean Breslow thickness of 6.6 mm (range 0 - 14.5) and patients from the 
WC with a mean Breslow thickness of 4.9 mm (range 0 - 22) (p=0.3602).
Conclusions. AMs accounted for a significant proportion of all CMs diagnosed. Patients presented with an advanced stage of disease at 
diagnosis, and further studies are needed to further investigate the reasons for delayed diagnosis.
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Objectives
To address deficiencies in the current literature by reviewing the 
clinical and pathological features of AM in an SA population.
Methods
This retrospective study included all patients diagnosed with AM 
at Tygerberg Academic Hospital (TAH), Cape Town, between 1 
January 2010 and 30 June 2016. AM was defined as all melanomas 
involving the palms, soles and nail apparatus, regardless of 
histological subtype.
All adult patients (≥18 years old, male or female) diagnosed with 
AM were included in the study. Exclusion criteria were: (i) patients 
aged <18 years; and (ii) inadequate clinical and demographic data 
available.
The National Health Laboratory Service (NHLS) information 
system at TAH was used to identify all patients diagnosed with CM 
within the set time frame. From this group all AM patients were 
identified. Epidemiological, clinical, radiological and histological 
data for AM patients were collected using the NHLS database, 
Picture Archiving and Communication System (PACS) and 
Enterprise Content Management (ECM) system at TAH.
A hot-deck imputation method was used for subjects where 
race/ethnicity was not indicated. Subjects were assigned to a 
group by comparing their surnames with a reference database 
of approximately 1.4 million surnames of known race/ethnicity. 
This method was constructed for the National Cancer Registry 
as a Statistical Analysis Software (SAS) program by the Data 
Management and Statistical Analysis Unit of the University of the 
Witwatersrand.[20]
Stata version 14 (StataCorp, USA) was used for data analysis. 
Descriptive statistics consisting of summary statistics (i.e. mean, 
range) for numerical data and frequencies for categorical data were 
used.
The study was carried out with the approval of the Stellenbosch 
University Human Subjects Research Ethics Committee (ref. no. 
S16/10/192). The need to obtain informed consent was waived, 
as this was a retrospective study and no identifying details were 
included.
Results
Using appropriate SNOMED codes to search the NHLS database 
yielded 335 patients diagnosed with CM at TAH between January 
2010 and June 2016. This group was further characterised in terms of 
demographics and clinical features, which are summarised in Table 1.
The location of the lesion was known in 293 patients, of whom 
66 (22.5%) had AM. Fig. 1 illustrates the distribution of all CMs 
diagnosed. AMs accounted for 80.0% of all CMs diagnosed in the 
black population compared with 8.0% and 34.0% in the white and 
coloured populations, respectively.
The 66 patients with AM were further analysed for patient, tumour 
and clinical management characteristics (Tables 2, 3 and 4).
The mean Breslow thickness of AM in male and female patients 
was 5.3 mm and 5.2 mm, respectively.
HIV status was known in 21 of the AM patients, and three of 
these patients were HIV-positive and presented with at least stage III 
metastatic disease (Table 5).
When comparing Breslow thickness of AM among ethnic groups, 
black patients presented with a mean Breslow thickness of 6.3 mm, 
white patients with 4.2 mm and coloured patients with 4.3 mm 
(p=0.1762).
Patients from outside the Western Cape Province (WC) (initial 
biopsy performed in another province) presented with a mean 
Breslow thickness of 6.6 mm (range 0 - 14.5) and patients from within 
the WC with a mean of 4.9 mm (range 0 - 22) (p= 0.3602).
Mean Breslow thickness for foot and hand AM was 4.9 mm 
(range  0 - 22) and 6.9 mm (range 0 - 13.3), respectively (p=0.2552).
Clinical management in the study cohort involved surgery, 
radiation and systemic therapy. Information regarding surgery was 
only available for 46 patients. Of the 34 patients (73.9%) who 
underwent surgery, 25 (73.5%) had wide local excision and 9 (26.5%) 
had an amputation.
Discussion
This study provides valuable scientific data on the demographics, 
clinical features and histopathology of patients diagnosed with AM 
in an SA population.
AMs accounted for 22.5% of all CMs diagnosed. This proportion 
is significantly higher than previously reported rates of AM, which 
range from 1% to 7%.[4,5] The problem with most large population-
based studies on AM is that they include mostly Caucasian patients. 
In contrast, studies from Hawaii, India and the French West Indies, 
where the populations largely consist of people with darker skin 
types, show AMs to represent up to 50% of all CMs diagnosed.[4] 
This supports the hypothesis of Durbec et al.[4] that, although rare, 
AM could represent an underestimated public health problem in 
countries mostly populated by people with darker skin types.
Table 1. Patient characteristics, all cutaneous melanomas 
diagnosed
Age at diagnosis (years) (N=329)
Mean (SD) 61.9 (15)
Median 62
Range 24 - 94
Gender (N=335), n (%)
Male 175 (52.2)
Female 160 (47.8)
Ethnic group (N=335), n (%)
Black 42 (12.5)
White 232 (69.3)
Coloured 57 (17.0)
Asian 1 (0.3)
Unknown 3 (0.9)
SD = standard deviation.
 
Figure 1: Location of all cutaneous melanomas diagnosed (n=293) 
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Fig. 1. Location of all CM’s diagnosed (N=293). (CM’s= cutaneous melanomas) 
Fig. 1. Location of all CMs diagnosed (N=293). (CMs = cutaneous mela­
nomas.)
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Data from this study on the male/female ratio were consistent 
with previous reports and showed that AM has a predilection for 
the female gender in this SA population.[5,6,15] The mean (standard 
deviation (SD)) age at diagnosis in the AM cohort was 61.5 (12.5) 
years. This was not significantly different from the mean (SD) age of 
all patients diagnosed with CM, which was 61.9 (15) years. Previous 
studies suggested that the median age at onset of AM is higher than 
that observed generally in other forms of CM, but this was not the 
case in the current study.[15]
It is well established in the literature that AM disproportionately 
afflicts darker-coloured skin, and our data support this finding.[3] In 
a large US-based study, Bradford et al.[3] reported the proportion of 
ALM in the USA to be 36% in the black population, 18% in Asian/
Pacific Islanders, 9% in Hispanic whites and only 1% in non-Hispanic 
whites. Previous studies from SA estimated the proportion of ALM 
in black individuals to be 60 - 70%,[15] and studies from Asia reported 
proportion rates between 47% and 86.6%.[5]
In this study, black patients accounted for 48.5% of all patients 
diagnosed with AM and constituted the largest ethnic group, followed 
by coloured and white patients, respectively.
The proportion of AMs among all CMs diagnosed in the black 
population was 80.0%, even higher than previously estimated. AMs 
accounted for 34.0% and 8.0% of CMs diagnosed in the coloured and 
white populations, respectively, and these figures are in keeping with 
previous reports.[5,11,21,22] The current study included only one Asian 
patient.
HIV status was known in 21 patients, of whom only three were HIV-
positive. Studies on the link between HIV infection and increased rates 
of melanoma are conflicting, with most studies not demonstrating an 
association.[23] All three HIV-positive patients presented at an advanced 
stage of disease that is generally associated with poor prognosis 
(Table 5). Two studies have investigated CM in HIV and showed that 
patients with HIV suffer increased melanoma mortality.[24,25]
With regard to tumour characteristics, more than 80% of AMs 
were located on the feet. These data are supported by previous reports 
that showed a lower prevalence of AM on the hands than on the 
feet. [3,5,10] When considering foot melanomas in the current study, 47 
(83.9%) were on the plantar aspect of the foot and the remainder on 
the toes and subungual areas. In 22 of the plantar AMs the heel was 
indicated as the exact location of the lesion. In the remainder, exact 
location was not specified. A study in Japan showed more AMs in 
the weight-bearing areas than in the non-weight-bearing areas of 
the plantar foot, suggesting that mechanical stress and shear force 
may play a role in the pathogenesis of these lesions.[26] This finding 
was recently challenged by a study from the USA that reported 
no significant difference in the distribution of AMs with regard to 
weight-bearing and non-weight-bearing regions.[27] In both the US 
and Japanese populations, AMs occurred more frequently on the heel 
than in the other areas of the plantar surface.
Table 3. Tumour characteristics of all acral melanomas 
diagnosed
Location (N=66), n (%)
Foot 56 (84.9)
Hand 10 (15.1)
Side (N=66), n (%)
Right 39 (59.1)
Left 27 (40.9)
Specific site (N=66), n (%)
Heel 22 (33.3)
Palm 3 (4.6)
Digit 7 (10.6)
Toe 9 (13.6)
Plantar (not specified) 25 (37.9)
Size at diagnosis (longest diameter in cm) (N=38)
Mean (SD) 3.8 (2.2)
Median 3
Range 1 - 9
Duration of lesion (months) (N=29)
Mean (SD) 14.7 (12.2)
Median 10
Range 2 - 48
Breslow thickness (mm) (N=51)
Mean (SD) 5.2 (4.6)
Median 4.2
Range 0 - 22
Ulceration (N=42), n (%)
Yes 31 (73.8)
No 11 (26.2)
Stage at diagnosis (N=41), n (%)
0 6 (14.6)
IA 1 (2.4)
IB 1 (2.4)
IIA 2 (4.9)
IIB 0
IIC 8 (19.5)
III 15 (36.6)
IV 8 (19.5)
SD = standard deviation.
Table 2. Patient characteristics, acral melanomas (N=66)
Age at diagnosis (years) 
Mean (SD) 61.5 (12.5)
Median 61.5
Range 26 - 88
Gender, n (%)
Male 24 (36.4)
Female 42 (63.6)
Ethnic group, n (%) 
Black 32 (48.5)
White 15 (22.7)
Coloured 18 (27.3)
Asian 1 (1.5)
HIV status, n (%)
Positive 3 (4.5)
Negative 18 (27.3)
Unknown 45 (68.2)
Patients from outside the Western Cape
Yes 17 (25.8)
No 49 (74.2)
Year diagnosed
2010 12 (18.2)
2011 11 (16.7)
2012 13 (19.7)
2013 11 (16.7)
2014 4 (6.1)
2015 9 (13.6)
2016 6 (9.1)
SD = standard deviation.
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Tumour characteristics in the current study were consistent with a 
delay in diagnosis and subsequent advanced disease at presentation. 
This was evident in tumour size, duration of lesion, tumour thickness 
and stage of disease at presentation.
Previous studies on AM reported a mean (SD) size at diagnosis of 
1.65 (1.1) cm.[10] In contrast, patients in the current study presented 
with a mean (SD) tumour size (longest diameter) at presentation of 
3.8 (2.2) cm.
A lengthy delay in the diagnosis of AM is well documented in 
the literature, ranging from 1 to 3.7 years. Factors that contribute 
to the delay in diagnosis include the hidden location, poor access 
to healthcare, disregard of the lesion by patients and misdiagnosis 
by healthcare providers.[15] The median duration of lesions at 
presentation in the current study was 10 months (range 2 - 48), which 
confirms delayed diagnosis of AM.
Tumour thickness, ulceration and an advanced stage of disease at 
presentation are considered major negative prognostic factors and 
relate to increased melanoma-specific mortality.[10] Several studies 
have also shown that AM typically presents with higher Breslow 
thickness compared with other forms of CM and therefore a poorer 
prognosis.[3,5,6] In a large German cohort (2 050 ALM patients) the 
mean Breslow thickness was 3.08 mm (median 2.2 mm),[5] which was 
in keeping with other studies on ALM from developed countries that 
reported a mean Breslow thickness between 2.51 mm and 2.8 mm at 
presentation.[6,15] York et al.[19] reported a mean Breslow depth of 4.13 
mm in ALMs diagnosed in the Northern Cape Province of SA. In 
the current study, mean Breslow thickness at diagnosis was 5.2 mm 
(median 4.2, range 0 - 22), suggesting that patients present much later 
than the norm in developed countries.
Complete histological data were only available for 42 of the 66 
patients. Ulceration was reported in 31 cases (73.8%). Again, this 
figure is significantly higher compared with other AM studies, where 
ulceration was reported in 33 - 47.9% of cases.[5,28]
The delay in diagnosis was further demonstrated in the study 
cohort by the advanced stage of disease at presentation. The majority 
of patients (56.1%) had at least stage III disease at diagnosis with 
metastatic disease. These data are in stark contrast to results from 
studies in other parts of the world. The German study showed 
that 77.4% of ALM patients had stage I or II disease and only 20% 
presented with some form of metastasis at diagnosis.[5] A recent 
study from South Korea showed similar results, with most patients 
presenting with stage I and II disease (80%).[28]
Although previous reports showed a greater Breslow thickness 
at diagnosis in male patients compared with female patients, no 
significant difference was demonstrated in this study.[3,15]
The poor prognosis of AM has in the past been attributed to 
the hidden location of foot AMs.[7] In the current study, the mean 
Breslow thickness for foot and hand melanomas was 4.9 mm 
(range 0 - 22) and 6.9 mm (range 0 - 13.3), respectively (p=0.2552), 
suggesting an equally poor prognosis for both groups. Although 
not statistically significant, this finding may support the hypothesis 
of Paolino et al.[7] that the poor prognosis associated with AM is 
not related to the hidden location of the lesion but rather to site-
specific clinicopathological features. In their study they reported 
no differences in terms of median Breslow thickness and survival 
between hand and foot AM.[7]
In the past race/ethnicity was also reported to be an independent 
prognostic factor,[29] but this point has been challenged by more 
recent studies.
Bradford et al.[3] used Surveillance, Epidemiology, and End Results 
(SEER) data to show that when controlled for thickness or stage, there 
were no statistical differences between 5- and 10-year melanoma-
specific survival rates in the different racial groups. The authors cited 
access to care and lack of awareness by patient and provider, resulting 
in delayed diagnosis, as contributing factors for worse AM survival 
in certain ethnic groups.[3]
This hypothesis was further supported by a recent US study that 
investigated a cohort with ALM with equal access to healthcare. 
Results from this study showed melanoma-specific mortality among 
patients with ALM not to be associated with race/ethnicity.[10] The 
poor prognosis generally observed among non-white patients was 
again attributed to the advanced tumour stage at presentation and 
limited access to clinical care.
Unequal access to healthcare is an unfortunate reality in SA and 
may explain our findings that showed AM in black patients to present 
with greater Breslow thickness. Mean Breslow thickness in the black 
population was 6.3 mm compared with 4.1 mm in the non-black 
groups (p=0.074).
Access to care as a factor contributing to more advanced disease 
at presentation was also demonstrated by the fact that patients from 
outside the WC presented with thicker tumours. Seventeen patients 
Table 5. Summary of HIV-positive patient characteristics
Patient no. Age (years) Gender Ethnic group
Size of tumour 
(cm)
Breslow thickness 
(mm) Stage
1 38 Female Black Unknown 22 IV
2 43 Male Black 1 × 1 4.2 III
3 51 Female Black 8 × 3 4.2 III
Table 4. Clinical management characteristics
Surgery (N=46), n (%)
Yes 34 (73.9)
No 12 (26.1)
Radiation (N=33), n (%)
Yes 11 (33.3)
No 22 (66.7)
Surgery type (N=34), n (%)
Wide local excision 25 (73.5)
Amputation 9 (26.5)
SLNB (N=34), n (%)
Yes 9 (26.5)
No 25 (73.5)
Lymph node dissection (N=34), n (%)
Yes 4 (11.8)
No  30 (88.2)
Systemic therapy (N=33), n (%)
Yes 1 (3.0)
No 32 (97.0)
Surgery waiting times (days) (N=32)
Mean (SD) 89 (91)
Median 60
Range 0-318
SLNB = sentinel lymph node biopsy; SD = standard deviation.
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(25.8%) in this cohort were from outside the WC, mostly from the 
Eastern Cape (EC). The mean Breslow thickness for these patients was 
6.6 mm compared with 4.9 mm for the patients who were from within 
the WC. According to the 2011 SA census,[30] the EC is predominantly 
a rural province with almost two-thirds of the population living in 
rural areas, which may limit access to healthcare.
Lack of awareness of AM on the part of patients and the general 
public and misdiagnosis by healthcare providers may also be factors 
contributing to a delayed diagnosis that need further investigation. 
Although it was not specifically measured in the current study, 
rates of clinical misdiagnosis in other studies ranged from 20% to 
50%. [15] Education of patients and healthcare providers, especially in 
countries with large populations of black patients, is therefore crucial 
to improve clinical diagnosis.
The median surgical waiting time in our study was 60 days (range 
0 - 318) compared with the median surgical interval for melanoma 
in the existing literature of 30 days.[31,32] A study from Scotland, 
however, showed no association between surgical intervals (≤14 days, 
15 - 28 days, 29 - 42 days and 43 - 91 days v. ≥92 days) and overall 
survival, disease-free survival or recurrence-free survival.[32] A study 
from the USA also found no association between overall survival or 
disease-free survival and surgical intervals of ≤28 days v. >28 days.[26] 
No formal international guidelines for surgical interval for melanoma 
exist, but informal guidelines recommend treatment within 4 - 6 
weeks.[33] The waiting time in this study was therefore reasonable and 
not a significant contributor to the advanced stage of disease.
Another reason for the poor prognosis of AM may be biological 
differences between AM and non-AM. Molecular genetic research 
has demonstrated that BRAF and NRAS mutations occur less 
frequently in ALM compared with other forms of CM and that 
mutations of the KIT gene have been observed more frequently in 
AM.[34,35] The current study did not involve genetic analysis, but 
this is an area that needs further investigation to better understand 
mutational variation in AM in the SA population.
Study limitations
This is a retrospective descriptive study with a small sample 
size. Quality and completeness of medical records were limiting 
factors. Treatment and follow-up data were also lacking. Complete 
histological data, including histological subtypes, were not available 
for all patients. Because of poor record keeping, outcomes could not 
be measured and survival data were therefore not included.
Conclusions
AM is a rare subtype of CM that carries a poor prognosis. The 
frequency of AM among all diagnoses of CM in SA appears higher 
than international published rates. The present study highlights 
the delay in diagnosis of AM in an SA population served by a 
large tertiary hospital, as illustrated by the size of the tumours at 
presentation, greater Breslow thickness and advanced stage of disease 
at diagnosis. Limited access to clinical care and delayed clinical 
diagnosis by healthcare providers probably contributed to delayed 
diagnosis. Further studies are needed to further delineate the reasons 
for the delayed diagnosis and to develop strategies to create public 
awareness and to educate healthcare workers in the early detection of 
AM. The paucity of information on genetic mutations specific to AM 
in the SA population justifies further study.
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